ESSA Pharma Inc. announced the appointment of Peter Virsik as Executive Vice President & Chief Operating Officer. Mr. Virsik will be responsible for leading ESSA's overall business development and corporate strategy as the company further advances its clinical development plan for the novel prostate cancer therapeutic EPI-506. Mr. Virsik is a seasoned biopharmaceutical executive with over 20 years' experience in corporate development, new product planning, licensing and alliance management with global pharmaceutical organizations. Prior to joining ESSA, Mr. Virsik served as Senior Vice President, Corporate Development for XenoPort (acquired by Arbor Pharmaceuticals).